World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
39997
World Ranking
15865
National Ranking
834

Arndt Vogel publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Arndt Vogel sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 541 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Arndt Vogel D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Arndt Vogel sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Arndt Vogel is affiliated with Hannover Medical School in Germany, contributing extensively to the field of medicine with a focus on oncology and hepatology. Their research spans a variety of topics related to cancer treatment, liver diseases, and cancer immunotherapy.

The scientist has been involved in significant research within these main fields of study:

  • Medicine

Their subfields of study include:

  • Oncology
  • Hepatology
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Epidemiology

Arndt Vogel's primary research topics cover:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Liver Disease Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Gallbladder and Bile Duct Disorders

Their publication record features numerous contributions to several key medical journals, including:

  • Journal of Clinical Oncology (67 publications)
  • Annals of Oncology (53 publications)
  • Journal of Hepatology (36 publications)
  • Zeitschrift für Gastroenterologie (16 publications)
  • Liver Cancer (11 publications)

Among their recent notable papers are:

  • "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study" (2020), The Lancet Oncology
  • "Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2022), Annals of Oncology
  • "NASH limits anti-tumour surveillance in immunotherapy-treated HCC" (2021), Nature
  • "Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial" (2023), The Lancet
  • "Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2022), Annals of Oncology

Collaboration has been an integral part of Vogel's work, with frequent co-authors including:

  • Anna Saborowski
  • Masatoshi Kudo
  • Lorenza Rimassa
  • Richard S. Finn
  • Bernhard Scheiner

Best Publications

  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han

  • BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.

    M. Reig;A. Forner;J. Rimola;J. Ferrer-Fábrega

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Vaibhav Sahai;Antoine Hollebecque;Gina Vaccaro

  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Dominik Pfister;Dominik Pfister;Nicolás Gonzalo Núñez;Roser Pinyol;Olivier Govaere

  • Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

    Andrew X. Zhu;Masatoshi Kudo;Eric Assenat;Stéphane Cattan

  • A comparison of fibrosis progression in chronic liver diseases

    Thierry Poynard;Philippe Mathurin;Ching-Lung Lai;Dominique Guyader

  • Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.

    A. Vogel;E. Martinelli;A. Cervantes;I. Chau

  • Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis.

    Arndt Vogel;Christian P. Strassburg;Michael P. Manns

  • Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    Sarah Berhane;Hidenori Toyoda;Toshifumi Tada;Takashi Kumada

  • Autoimmune hepatitis, from mechanisms to therapy.

    Michael P. Manns;Arndt Vogel

  • Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

    A. Vogel;A. Cervantes;I. Chau;B. Daniele

  • Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury.

    Jutta Lamlé;Silke Marhenke;Jürgen Borlak;Reinhard von Wasielewski

  • GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.

    Jan Best;Lars P. Bechmann;Jan-Peter Sowa;Svenja Sydor

  • Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.

    Ursula Ehmer;Arndt Vogel;Jan Karl Schütte;Britta Krone

  • Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.

    Bernhard Scheiner;Katharina Pomej;Martha M. Kirstein;Florian Hucke

  • The RENAISSANCE (AIO-FLOT5) Trial: Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of the German AIO/CAO-V/CAOGI

    Salah-Eddin Al-Batran;Thorsten O Goetze;Daniel W. Mueller;Arndt Vogel

  • Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

    Lucie Heinzerling;Thomas K Eigentler;Michael Fluck;Jessica C Hassel

  • Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment

    Elad Horwitz;Ilan Stein;Mariacarla Andreozzi;Julia Nemeth

  • UDP Glucuronosyltransferase (UGT1A7) Gene Polymorphisms Increase the Risk of Chronic Pancreatitis and Pancreatic Cancer

    Johann Ockenga;Arndt Vogel;Niels Teich;Volker Keim

Frequent Co-Authors

Michael P. Manns
Michael P. Manns Hannover Medical School
Masatoshi Kudo
Masatoshi Kudo Kindai University
Christian P. Strassburg
Christian P. Strassburg University Hospital Bonn
Andrew X. Zhu
Andrew X. Zhu Harvard University
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Juan W. Valle
Juan W. Valle University of Manchester
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University
Robert Geffers
Robert Geffers Helmholtz Centre for Infection Research
Stephen L. Chan
Stephen L. Chan Chinese University of Hong Kong
Josep M. Llovet
Josep M. Llovet University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering alternative pathways in the medical field? Many students start with accessible healthcare programs to build foundational skills or jumpstart their careers. For example, medical billing and coding schools with financial aid offer a fast, affordable entry into healthcare administration, often completed fully online.

Those interested in patient care, but who want to avoid intense entrance testing, can explore nursing school no entrance exam programs. These options make nursing more accessible for qualifying students.

For leadership-minded individuals, the best online healthcare administration degree programs provide flexible learning and direct pathways to administrative roles in hospitals, clinics, and other care settings.

Registered nurses looking to advance further can benefit from adn to fnp bridge programs, which make it possible to become a Family Nurse Practitioner without starting over.

These diverse remote and hybrid health degrees expand your career options and make studying medicine in the USA more accessible than ever.

Best Scientists Citing Arndt Vogel

Trending Scientists

Recently Published Articles